Cellectis (CLLS) Free Cash Flow Growth (5y) (2020 - 2026)
Cellectis (CLLS) Free Cash Flow Growth (5y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn |
| 10 | Cellectis | 285.51 Mn | 99.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.29% |
| Dec 31, 2025 | 25.88% |
| Sep 30, 2025 | 54.16% |
| Jun 30, 2025 | -3.95% |
| Mar 31, 2025 | -30.53% |
| Dec 31, 2024 | 31.31% |
| Sep 30, 2024 | 21.71% |
| Jun 30, 2024 | 37.54% |
| Mar 31, 2024 | -2.33% |
| Dec 31, 2023 | 26.45% |
| Sep 30, 2023 | -4.02% |
| Jun 30, 2023 | -7.36% |
| Mar 31, 2023 | -6.21% |
| Dec 31, 2022 | 30.90% |
| Sep 30, 2022 | -8.52% |
| Jun 30, 2022 | -11.44% |
| Mar 31, 2022 | -13.10% |
| Dec 31, 2021 | -89.85% |
| Sep 30, 2021 | -115.98% |
| Jun 30, 2021 | 3.60% |